American Association for Cancer Research
Browse
21598290cd130005-sup-supp_legends.pdf (110.02 kB)

Supplementary Data Figure Legends from Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

Download (110.02 kB)
journal contribution
posted on 2023-04-03, 20:21 authored by Michael P. O'Connell, Katie Marchbank, Marie R. Webster, Alexander A. Valiga, Amanpreet Kaur, Adina Vultur, Ling Li, Meenhard Herlyn, Jessie Villanueva, Qin Liu, Xiangfan Yin, Sandy Widura, Janelle Nelson, Nivia Ruiz, Tura C. Camilli, Fred E. Indig, Keith T. Flaherty, Jennifer A. Wargo, Dennie T. Frederick, Zachary A. Cooper, Suresh Nair, Ravi K. Amaravadi, Lynn M. Schuchter, Giorgos C. Karakousis, Wei Xu, Xiaowei Xu, Ashani T. Weeraratna

PDF file 110K, Figure legends for Supplementary Data

History

ARTICLE ABSTRACT

An emerging concept in melanoma biology is that of dynamic, adaptive phenotype switching, where cells switch from a highly proliferative, poorly invasive phenotype to a highly invasive, less proliferative one. This switch may hold significant implications not just for metastasis, but also for therapy resistance. We demonstrate that phenotype switching and subsequent resistance can be guided by changes in expression of receptors involved in the noncanonical Wnt5A signaling pathway, ROR1 and ROR2. ROR1 and ROR2 are inversely expressed in melanomas and negatively regulate each other. Furthermore, hypoxia initiates a shift of ROR1-positive melanomas to a more invasive, ROR2-positive phenotype. Notably, this receptor switch induces a 10-fold decrease in sensitivity to BRAF inhibitors. In patients with melanoma treated with the BRAF inhibitor vemurafenib, Wnt5A expression correlates with clinical response and therapy resistance. These data highlight the fact that mechanisms that guide metastatic progression may be linked to those that mediate therapy resistance.Significance: These data show for the first time that a single signaling pathway, the Wnt signaling pathway, can effectively guide the phenotypic plasticity of tumor cells, when primed to do so by a hypoxic microenvironment. Importantly, this increased Wnt5A signaling can give rise to a subpopulation of highly invasive cells that are intrinsically less sensitive to novel therapies for melanoma, and targeting the Wnt5A/ROR2 axis could improve the efficacy and duration of response for patients with melanoma on vemurafenib. Cancer Discov; 3(12); 1378–93. ©2013 AACR.This article is highlighted in the In This Issue feature, p. 1317